JANX

Janux Therapeutics, Inc.

NasdaqGMUSDEQUITY DELAYED

17.45

▲ 0.17 (0.98%)

MARKET · —

Price

Open

17.49

Prev close

17.28

Day high

17.70

Day low

17.23

Volume

501.59K

Market cap

—

P/E (TTM)

—

52W range

12.12 – 35.34

Trailing performance

Price return · vs SPY

Returnvs SPY

+7.88% +9.2%

+10.62% +6.9%

+20.68% +17.6%

+32.95% +21.9%

YTD

+26.01% +13.7%

-30.08% -50.1%

+55.55% -18.6%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

16.71

+4.41% from price

SMA 20

16.13

+7.80% from price

SMA 50

15.61

+11.42% from price

SMA 100

15.05

+15.93% from price

SMA 200

16.03

+8.46% from price

EMA 12

16.68

+4.63% from price

EMA 26

16.23

+7.55% from price

EMA 50

15.77

+10.69% from price

RSI (14)

64.3

Neutral

MACD (12,26,9)

0.45

Hist 0.13

ATR (14)

0.59

3.41% of price

Realised vol 30D

37.4%

Annualised

Bollinger upper

17.62

20, 2σ

Bollinger lower

14.65

20, 2σ

50 / 200 cross

Death

15.61 vs 16.03

Trend bias

Above 200

+8.46%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.13

More volatile than market

Correlation to SPY

0.20

Largely independent

Realised vol 30D

37.4%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-64.9%

Peak to trough

Max drawdown 5Y

-83.0%

Peak to trough

ATR 14

0.59

3.41% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 17.45

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

JANX · links out to the publisher

Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile Simply Wall St. · 11d ago RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating MT Newswires · 12d ago Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates Zacks · 16d ago Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights Business Wire · 16d ago 3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership Simply Wall St. · 29d ago Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? Simply Wall St. · 44d ago VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · 51d ago Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? Insider Monkey · 53d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.